The excimer laser: Science fiction fantasy or practical tool?

被引:17
作者
Biamino, G [1 ]
机构
[1] Univ Leipzig, Ctr Heart, Dept Med Cardiol, D-04289 Leipzig, Germany
关键词
excimer laser; atherectomy; critical limb ischemia; angioplasty;
D O I
10.1583/04-1394.1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Nearly 20 years ago, in vitro experiments left no doubt about the fact that laser light can ablate atherosclerotic plaque. The initial enthusiastic results with the technology, particularly in coronary arteries, were followed by reports showing unacceptably high restenosis and complication rates. These poor results were due to the premature application of an underdeveloped technology, a lack of understanding of laser/tissue interaction, and the use of incorrect lasing techniques. Consequently, and without discrimination, all lasers were banned from the catheterization laboratories for nearly a decade. Technological enhancements of the excimer laser, combined with refined catheter lasing techniques, resulted in greater debulking of atherosclerotic material in long superficial femoral artery occlusions. These results triggered the application of the excimer laser technique as an atherectomy tool in more complex lesions below the knee. The multicenter Laser Atherectomy for Critical Ischemia study clearly demonstrated that the excimer laser technology resulted in limb salvage rates >90% in patients with critical limb ischemia (CLI). Furthermore, new clinical results indicate that the excimer laser is very effective in dissolving thrombotic obstructions, redirecting this technology to the coronary field. The results of the excimer laser in CLI validate the role of the cool laser in treating complex peripheral vascular disease. The results suggest a larger indication for this technology and support a more aggressive use of these interventional techniques in the treatment of this large patient cohort. However, all lasers are not equally effective in debulking atherosclerotic material. Only the athermic process associated with the excimer laser produces a safe and effective endovascular ablation of obstructive atherosclerotic and/or thrombotic material. The appropriate and safe utilization of the equipment and lasing techniques, combined with correct indications and patient selection, will contribute to the successful application of laser-assisted atherectomy in complex peripheral and coronary artery obstructive disease. Unfortunately, little consistent scientific data has been generated to convince the interventional community of the usefulness of excimer laser ablation.
引用
收藏
页码:207 / 222
页数:16
相关论文
共 71 条
[1]   A model for evaluation of arterial thrombosis following interventional procedures [J].
Abela, GS ;
Hage-Korban, E ;
Tomaru, T ;
Barbeau, GR ;
Friedl, SE ;
Kaelin, LD ;
Seeger, JM .
LASERS IN MEDICAL SCIENCE, 2001, 16 (02) :141-147
[2]   INVITRO EFFECTS OF ARGON-LASER RADIATION ON BLOOD - QUANTITATIVE AND MORPHOLOGIC ANALYSIS [J].
ABELA, GS ;
CREA, F ;
SMITH, W ;
PEPINE, CJ ;
CONTI, CR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 5 (02) :231-237
[3]   LASER ARTERIAL RECANALIZATION - A CURRENT PERSPECTIVE [J].
ABELA, GS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (01) :103-105
[4]  
ALLIE DE, 2003, TRANSC CARD THER TCT
[5]   Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease [J].
Appelman, YEA ;
Piek, JJ ;
Strikwerda, S ;
Tijssen, JGP ;
deFeyter, PJ ;
David, GK ;
Serruys, PW ;
Margolis, JR ;
Koelemay, MJ ;
vanSwijndregt, EWJM ;
Koolen, JJ .
LANCET, 1996, 347 (8994) :79-84
[6]   Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts [J].
Baim, DS ;
Wahr, D ;
George, B ;
Leon, MB ;
Greenberg, J ;
Cutlip, DE ;
Kaya, U ;
Popma, JJ ;
Ho, KKL ;
Kuntz, RE .
CIRCULATION, 2002, 105 (11) :1285-1290
[7]  
Bejarano J, 1999, Arq Bras Cardiol, V73, P149
[8]  
Belgrano EA, 1996, EUR J VASC ENDOVASC, V11, P112
[9]   Prostanoids for chronic critical leg ischemia -: A randomized, controlled, open-label trial with prostaglandin E1 [J].
Belgrano, EA ;
Guala, A ;
Mazzucchetti, S ;
Marinoni, V ;
Calzoni, D ;
Bedoni, P ;
Confalonieri, MA ;
Agus, GB ;
Mondani, P ;
De Angelis, R ;
Biasi, GM ;
Piglionica, MR ;
Abbritti, F ;
Agrifoglio, G ;
Costantini, A ;
Della Vedova, MR ;
Miglierina, L ;
Marrocu, R ;
Bragherio, G ;
Zanoni, CE ;
Borin, F ;
Alderi, G ;
Emanuelli, G ;
Colzani, M ;
Ponti, GB ;
Berra, S ;
Bevilacqua, A ;
Bocca, M ;
Invernizzi, C ;
De Angelis, E ;
Tacconi, A ;
D'Angelo, F ;
Vaghi, M ;
Arzini, A ;
Boccalon, L ;
Losapio, GM ;
Ambrosi, R ;
Briolini, F ;
Inzoli, MR ;
Lombardi, G ;
Tarantola, P ;
Zocca, N ;
Tenchini, P ;
Fontanili, M ;
Guidetti, D ;
Pedeferri, G ;
Bordoni, MC ;
Catalano, A ;
Visconti, W ;
Vedovato, F .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (05) :412-+
[10]  
BIAMINO G, 2003, ENDOVASCULAR TODAY, V2, P45